Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

81. Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Scottish Medicines Consortium2017

82. Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States

Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States 28840197 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Associations of Protein-Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States. 390-399 10.1016/j.ekir.2017.01.002 It is unknown (...) whether the criteria used to define Protein-energy wasting (PEW) syndrome in dialysis patients reflect protein or energy wasting in the general and moderate CKD populations. In 11,834 participants in the 1999-2004 National Health and Nutrition Examination Survey, individual PEW syndrome criteria and the number of PEW syndrome categories were related to lean body and fat masses (measured by dual-energy absorptiometry) using linear regression in the entire cohort and CKD sub-population. Serum chemistry

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

83. Chronic kidney disease: the global challenge.

Chronic kidney disease: the global challenge. The worldwide rise in the number of patients with chronic kidney disease (CKD) and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach epidemic proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of end-stage renal disease (ESRD) to much more aggressive primary and secondary (...) prevention is therefore imperative. In this Seminar, we examine the epidemiology of CKD worldwide, with emphasis on early detection and prevention, and the feasibility of methods for detection and primary prevention of CKD. We also review the risk factors and markers of progressive CKD. We explore current understanding of the mechanisms underlying renal scarring leading to ESRD to inform on current and future interventions as well as evidence relating to interventions to slow the progression of CKD

Lancet2017

84. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) American Journal of Kidney Diseases Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor

National Kidney Foundation2017

85. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIET Y OF NEPHROLOGY VOLUME 7 | ISSUE 1 | JULY 2017 www.kisupplements.org KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) KISU_v7_i1_COVER.indd 1 KISU_v7_i1_COVER.indd 1 31-05 (...) -2017 13:23:05 31-05-2017 13:23:05KDIGO 2017 CLINICAL PRACTICE GUIDELINE UPDATE FOR THE DIAGNOSIS, EVALUATION, PREVENTION, AND TREATMENT OF CHRONIC KIDNEY DISEASE–MINERAL AND BONE DISORDER (CKD-MBD) Kidney International Supplements (2017) 7, 1–59 1KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and TreatmentofChronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 3 Tables and supplementary material 6 KDIGO Executive Committee 7 Reference keys 8 CKD

National Kidney Foundation2017

86. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7

National Guideline Clearinghouse (partial archive)2017

92. Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

DynaMed Plus2017

95. Chronic kidney disease

Chronic kidney disease Chronic kidney disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic kidney disease Last reviewed: August 2018 Last updated: November 2017 Summary Proteinuria or haematuria, and/or a reduction in the GFR for more than 3 months' duration. The most common causes are diabetes mellitus (DM) and hypertension (HTN). The majority of people are asymptomatic, and the diagnosis is determined (...) only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of BP are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronic kidney disease, also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the GFR to <60 mL/minute/1.73 m^2 for ≥3 months' duration. KDOQI Advisory Board Members. Clinical practice guidelines

BMJ Best Practice2017

96. Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease

Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease ABCD-RA Clinical Practice Guidelines – Lipid management in DN &/or DM CKD. Online June 2017 © ABCD-RA 2017 1 CONTENTS Introduction ……………………………………. 2 Rationale for guidelines 22-24 ………… 14 Methodology…………………………………… 2 Rationale for guidelines 25-28 ……….. 15 Why do we need these guidelines (...) : +44 (0) 141 201 1100 E-mail: Patrick.mark@glasgow.ac.uk 2 Dr Peter Winocour East and North Herts Institute of Diabetes and Endocrinology (ENHIDE), Queen Elizabeth II Hospital, Welwyn Garden City, AL7 4HQ, UK Tel +44 (0) 1438 288324 E-mail: peter.winocour@nhs.net Address for correspondence & Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease

Association of British Clinical Diabetologists2017

97. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) blockade in patients with type 2 diabetes, nephropathy and/or early chronic kidney disease (stages 1–3) 13 Recommendations 14 Audit standards 14 Areas that require further research 15 Introduction 15 The renin-angiotensin-aldosterone system 16 Hypertension in patients with type 2 diabetes 16 The role of home and ambulatory blood pressure measurement 16 Lifestyle modification and impact on blood pressure 17 Blood pressure lowering agents 18 RAAS blockade in patients with type 2 diabetes without

Association of British Clinical Diabetologists2017

98. Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population

Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population 29318214 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population. 366-379 10.1016/j.ekir.2016.12.007 High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function decline in individuals with renal tubular diseases. It is not known whether this association also exists (...) in the general population. Therefore, we investigated whether high UCaE is associated with risk of developing chronic kidney disease (CKD) in community-dwelling subjects. Urine samples of 5491 subjects who were free of CKD at baseline and participated in the Prevention of Renal and Vascular End-Stage Disease study (a prospective, observational, general population-based cohort of Dutch men and women aged 28-75 years) were examined for UCaE. UCa concentration was measured in two 24-hour urine samples

Kidney international reports2016 Full Text: Link to full Text with Trip Pro

99. Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial 29142966 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled (...) Clinical Trial. 380-389 10.1016/j.ekir.2016.12.008 Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity ( T 50 ) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline

Kidney international reports2016 Full Text: Link to full Text with Trip Pro

100. Chronic Kidney Disease.

Chronic Kidney Disease. The definition and classification of chronic kidney disease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m 2 , or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause. Diabetes and hypertension are the main causes of CKD in all high-income and middle-income countries, and also (...) measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease

Lancet2016